ATF4 protects against neuronal death in cellular Parkinson's disease models by maintaining levels of parkin
about
Emerging preclinical pharmacological targets for Parkinson's diseaseAdaptive preconditioning in neurological diseases – therapeutic insights from proteostatic perturbationsLimited ATF4 Expression in Degenerating Retinas with Ongoing ER Stress Promotes Photoreceptor Survival in a Mouse Model of Autosomal Dominant Retinitis PigmentosaSTEP61 is a substrate of the E3 ligase parkin and is upregulated in Parkinson's diseaseLuteolin modulates 6-hydroxydopamine-induced transcriptional changes of stress response pathways in PC12 cellsRTP801/REDD1: a stress coping regulator that turns into a troublemaker in neurodegenerative disordersMolecular pathway of near-infrared laser phototoxicity involves ATF-4 orchestrated ER stressTranscriptional and metabolic adaptation of human neurons to the mitochondrial toxicant MPP(+)Midnolin is a novel regulator of parkin expression and is associated with Parkinson's DiseaseParkin loss of function contributes to RTP801 elevation and neurodegeneration in Parkinson's disease.Trib3 Is Elevated in Parkinson's Disease and Mediates Death in Parkinson's Disease Models.Prevention of the degeneration of human dopaminergic neurons in an astrocyte co-culture system allowing endogenous drug metabolismAltered machinery of protein synthesis is region- and stage-dependent and is associated with α-synuclein oligomers in Parkinson's disease.MPP+-induces PUMA- and p53-dependent, but ATF3-independent cell death.ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death.Activation of GCN2 kinase by ribosome stalling links translation elongation with translation initiation.Loss of NEDD4 contributes to RTP801 elevation and neuron toxicity: implications for Parkinson's disease.Parkin Overexpression Ameliorates PrP106-126-Induced Neurotoxicity via Enhanced Autophagy in N2a Cells.Mitochondria-Associated Membranes (MAMs): Overview and Its Role in Parkinson's Disease.The role of endoplasmic reticulum stress in neurodegenerative disease.PINK1 and Parkin are genetic modifiers for FUS-induced neurodegeneration.The endoplasmic reticulum-mitochondria interface is perturbed in PARK2 knockout mice and patients with PARK2 mutations.Up-regulation of activating transcription factor 4 induces severe loss of dopamine nigral neurons in a rat model of Parkinson's disease.Activating transcription factor 4 (ATF4) modulates post-synaptic development and dendritic spine morphologyPhysiological/pathological ramifications of transcription factors in the unfolded protein response.The Gcn4 transcription factor reduces protein synthesis capacity and extends yeast lifespan.Mitochondrial dysfunction induces dendritic loss via eIF2α phosphorylationFosB and ΔFosB expression in brain regions containing differentially susceptible dopamine neurons following acute neurotoxicant exposure.Neurotoxin mechanisms and processes relevant to Parkinson's disease: an update.Oxidative stress and cellular pathologies in Parkinson's disease.Mutations in THAP1/DYT6 reveal that diverse dystonia genes disrupt similar neuronal pathways and functions.MPP+-Lesioned Mice: an Experimental Model of Motor, Emotional, Memory/Learning, and Striatal Neurochemical Dysfunctions.Neurodegeneration: Keeping ATF4 on a Tight Leash.Guanabenz promotes neuronal survival via enhancement of ATF4 and parkin expression in models of Parkinson disease.Implication of KRT16, FAM129A and HKDC1 genes as ATF4 regulated components of the integrated stress response.Brain-Derived Neurotrophic Factor Elevates Activating Transcription Factor 4 (ATF4) in Neurons and Promotes ATF4-Dependent Induction of Sesn2.Gensenoside Rb1 protects rat PC12 cells from oxidative stress-induced endoplasmic reticulum stress: the involvement of thioredoxin-1.A monocyte gene expression signature in the early clinical course of Parkinson's disease
P2860
0b0362e1b5d837d7d90351a466538694b93c93ee4646fb53daab6c993246048d7576dcdefebabfd04cf11f13e4903e4e3289dfad20885de99d26017e8533bb16e65af0b91f1d43f12c8405010c2a5b258ff81df63f8ed06bd583d1c5d1e4b1b956d7aedfad619c5d72c2dec2dd21221921a84521de318e84b7fa3718fcd9792da713b5c81ba84cd370b26308feeb46f6caa9f6c11200cc5cb1cc06569dff16f6
P248
Q26764724-58166B5A-4671-416D-96AC-C27AFE709087Q26765956-4B2DDCC9-1FCD-43A1-AEBD-C8EB0449E32AQ27348512-2295DEBF-4414-47A2-8E9C-B608F69133C3Q28255428-45D62201-9E52-448E-9958-AB73AFEA28DAQ28386347-BA1340E9-9822-4C34-ABBC-8AE10CDD0FF4Q28395230-8DAC0AAF-396C-4319-AF8C-F5F00C523598Q30652544-FF86842B-25A0-4BEA-983C-A811AC907274Q33720121-DD18DB76-D31A-46C7-B3F4-005CB0D3F308Q33918418-E75ADE40-F45B-4AFF-8FBE-D3D46EA4EEC2Q35679526-95B4277C-9EE4-4D06-8996-D7C377538B9EQ35897729-3505E510-DE1C-4A82-B96A-02E618FDEC60Q35978121-038B8B44-5469-420F-B051-E88CFF2DCF2CQ36336723-D00505E8-6BDA-4D97-B93A-7A85158387BEQ36839378-919B8893-33E1-47F5-8364-686381AA7DADQ36954378-73EC9939-DE8C-4DAA-B238-DB23F63FD133Q37029489-6563EAF4-4F6A-478C-920A-69EC0E80DE60Q37644778-AF9ADECD-E907-4137-84C2-E742D5A47A3CQ38757376-D82969F0-7D1A-4E9E-A122-98A44C9DC9DAQ38974698-47FEC0A0-58EE-4EEB-8998-C4E90346447EQ38999268-290D486B-908A-4AEA-8B0A-CC43F554B70EQ39235670-454B536B-03F8-43ED-B81B-D4D03E54A77CQ39748670-76982EDA-DE06-4072-91E9-189CECC7B6E8Q40732376-F26FB147-824D-40AB-9FC1-16E6483DFD19Q41481375-FDF504B5-A7A2-4B52-935D-F908276D2CCCQ41583320-8170C158-9D70-47FE-A352-383EDA047AC2Q41630273-2EB1BF49-F696-41F3-B192-9988F2009558Q42316937-93D37449-0EE1-4761-9E61-AD666F74D452Q42391380-4AF8065A-0082-4ECD-A1C4-EC67841B3403Q43679571-8602FA28-38FF-4EBB-8099-26C33D3B8743Q46252606-30250948-5536-45BA-B1C6-21AABCAF1F93Q47647686-6493488B-21BD-4636-8F15-A8BD8BEB84C2Q48483209-BCCFD693-0ABE-43D2-AC9A-45C5312D5A49Q48540839-09C7EE52-E5C0-46D1-AD2C-EC70BD59EA7AQ50060994-044517CB-90B8-4DFF-B188-D02C4F4EBDA9Q50114592-3AFE215A-2402-4E7F-A59D-22C047A1A057Q52337542-47EC509C-3D1C-4450-AB4B-E2EECCFA24CFQ53354169-3C7BBF2C-CA0E-42BD-BA34-563562717696Q57175718-20C1544E-E605-43AC-9C3F-BA9C08D60AE7
P2860
ATF4 protects against neuronal death in cellular Parkinson's disease models by maintaining levels of parkin
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
ATF4 protects against neuronal ...... y maintaining levels of parkin
@ast
ATF4 protects against neuronal ...... y maintaining levels of parkin
@en
ATF4 protects against neuronal ...... y maintaining levels of parkin
@en-gb
ATF4 protects against neuronal ...... y maintaining levels of parkin
@nl
type
label
ATF4 protects against neuronal ...... y maintaining levels of parkin
@ast
ATF4 protects against neuronal ...... y maintaining levels of parkin
@en
ATF4 protects against neuronal ...... y maintaining levels of parkin
@en-gb
ATF4 protects against neuronal ...... y maintaining levels of parkin
@nl
prefLabel
ATF4 protects against neuronal ...... y maintaining levels of parkin
@ast
ATF4 protects against neuronal ...... y maintaining levels of parkin
@en
ATF4 protects against neuronal ...... y maintaining levels of parkin
@en-gb
ATF4 protects against neuronal ...... y maintaining levels of parkin
@nl
P2093
P2860
P3181
P1476
ATF4 protects against neuronal ...... y maintaining levels of parkin
@en
P2093
Cristina Malagelada
John F Crary
Lloyd A Greene
Oren A Levy
Xiaotian Sun
P2860
P304
P3181
P356
10.1523/JNEUROSCI.2292-12.2013
P407
P50
P577
2013-02-06T00:00:00Z